However, it is still not clear whether SGLT2 inhibitors have a direct effect on sodium transporter at renal ... the persistent urinary glucose excretion is accompanied by compensatory hyperphagia ...

As a class, sodium–glucose transporter 2 inhibitors are novel drugs initially developed for glycemic control in patients with type 2 diabetes. [Cowie MR, et al. Nat Rev Cardiol. 2020;1a] Their ...

Type 2 diabetes is a major health problem in the 21st century, with increasing rates of obesity both driving up the number of patients affected and reducing the age at diagnosis. Drugs that lower ...

Use of sodium-glucose co-transporter 2 (SGLT-2) inhibitors is currently classified as off-label in individuals less than 18 years of age in Canada. Use of SGLT-2 inhibitors may result in euglycemic ...

Learn more about the different types, as well as the benefits and side effects. Sodium-glucose transport protein 2 (SGLT2) inhibitors are a class of medications used to treat type 2 diabetes.

Sodium-glucose transporter 2 (SGLT2) inhibitors are safe and well-tolerated in people with heart failure (HF) related to adult congenital heart disease (ACHD) and associated with reduced ...

Now, researchers from Japan have uncovered novel molecular mechanisms underlying the senolytic effects of canagliflozin—a sodium glucose co-transporter 2 inhibitor used to control blood glucose ...

(An active ingredient is what makes a drug work.) It belongs to a group of drugs called sodium-glucose transport protein 2 (SGLT2) inhibitors. SGLT2 inhibitors are a group of prescription ...

They are designed to lower high blood glucose levels typical in T2DM, and work by inhibiting the sodium-glucose transport protein 2. SGLT2i have also been shown to improve outcomes among patients with ...